Developments in targeted AML therapies: venetoclax, quizartinib & amp; gilteritinib
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, speaks about three new target...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
New technologies informing SOC in DLBCL
Chemotherapy is ineffective against a certain subset of diffuse large B-cell lymphoma (DLBCL) types. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, hel...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
CAVEAT: venetoclax and high dose chemo for elderly AML
Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, presented results from the CAVEAT trial (ACTRN12616000445471) at the 23rd Congress of the European Hematological Association (EHA) 20...
Author: VJHemOnc
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel BTK inhibitors for Waldenstrms macroglobulinemia
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenstrms macroglobulinemia (WM) from the 23rd congress of European Hematology Assoc...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Improved survival in MM with thalidomide before and after ASCT
The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data from multiple myeloma (MM) trials. In this interview, Niels van de Donk, MD, Ph...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Multiple Myeloma trial highlights: ARROW, OPTIMISMM & amp; ALCYONE
The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data from their recent clinical trials. In this video, Mohamad M...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
iNNOVATE results: a prospective new standard of care for Waldenstrms macroglobulinemia
The purpose of the iNNOVATE study (NCT02165397) was to evaluate the safety and efficacy of ibrutinib and rituximab for the treatment of Waldenstrms macroglobulinemia (WM). Here, at the 23rd congress...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Key factors in the tumor-tumor microenvironment relationship in myeloma
Bruno Paiva, PhD, from the University of Navarra, Navarra, Spain, shares insights into multiple myeloma (MM) from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sw...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Biomarkers in lymphoma
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockh...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
MAJIC update: promising results for ruxolitinib in PV and ET
Claire Harrison, MD, FRCP, FRCPath, from Guy's and St Thomas' Hospital, London, UK, presented updates and results from the MAJIC clinical trial (ISRCTN61925716) at the 23rd Congress of the European He...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Treatment challenges in myelofibrosis
Treating myelofibrosis is accompanied by several complications that must be considered, including thrombocytopenia and anemia. In this video, recorded at the 23rd Congress of the European Hematology A...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Reflections on an excellent EBMT 2018
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting congress with >5,000 delegates in attendance - the highest attenda...
Author: VJHemOnc
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
CODE and the UK Oncology Forum: promoting international collaboration
Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Dr Woolmore, Initiative Lead, Collaboration for Oncology Data in Europe (CODE), points to the advantage of congresses like the UK OF...
Author: VJOncology
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD is the best predictor for treatment success in AML
Measurable residual disease (MRD) is gaining traction not only as a prognostic indicator, but also as a tool for informing treatment plans. In this video, recorded at the 23rd Congress of the European...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL
Paolo Ghia, MD, of the Universit Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583) at the 23rd Congress of the European Hematology Associatio...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
